Actos Lawsuit Settlement News: Takeda Agrees to Pay $2.3 Billion Settlement, Says Lawsuitsettlementnews.com
Lawsuit Help Center website reports that Takeda Pharmaceutical Co. has agreed to a settlement which amounts to awards of more than $296K average settlement values per case for plaintiffs who choose to participate in the settlement agreement, resolving approximately 8K cases against the company over Actos involving bladder cancer patients.
NEW ORLEANS, May 12, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co. has agreed to pay $2.37 billion to settle approximately 8,000 federal and state lawsuits over its drug Actos. The 8K cases include 3,500 lawsuits in Lafayette, Louisiana before U.S. District Judge Rebecca Doherty (In Re: Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana), and about 4,500 suits in California, Pennsylvania, Illinois, and West Virginia, according to Bloomberg News. The claimants alleged that Takeda hid the bladder cancer risks of the diabetes drug, however, according to Drug Watch, Takeda insists that the benefits of Actos far outweigh the side effects.
Takeda officials announced that they will put the money into a settlement fund if 95% of plaintiffs agree to participate in the settlement; and if 97% of the plaintiffs sign up, the drug maker would add an additional $300 million, raising the settlement to $2.4 billion, according to Bloomberg News. Settlement awards would be more than $296,000 per case for plaintiffs who choose to participate in the settlement, but settlement amounts may be reduced depending on certain factors such as age, smoking history, and toxin exposure.
Chris Janish, CEO of MTS, commented on the recent Actos settlement, "It is great to see that a litigation over a drug that has produced serious side effects such as bladder cancer is starting to come to a final resolution. Although many patients and their family members will never be the same, a settlement of this size speaks volumes on many levels. Takeda is trying to move forward and also stop new lawsuit claims from coming in, however, possible victims of bladder cancer from Actos should not be deterred and should seek counsel before it is too late to claim their potential award like the rest of the plaintiffs."
MTS is ready and able to assist those who need lawsuit help with obtaining an Actos law firm or Actos lawyer to provide a free evaluation on their specific case. To learn more about MTS' services involving Actos and other bad drug litigations, please visit: http://www.lawsuitsettlementnews.com/actos-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance or lawsuit money, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can assist you with these services. Injured parties from Actos usage and/or complications can apply for up to $100K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit: http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have suffered complications from Actos and need lawsuit money or lawsuit help, including finding an Actos attorney or law firm, please call 877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.com and an agent will contact you shortly.
Disclaimer: MT Services LLC, operator of Lawsuitsettlementnews.com, is not a law firm and cannot provide legal advice on your case; however, MTS works with lawyers involved in mass tort litigations who are willing to provide a free legal consultation at the consumer's request. For a list of full disclosures please visit the company's website disclosure page.
Contact: |
Chris Janish, CEO |
Ph. 877.571.0405 |
SOURCE MT Services LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article